Results 141 to 150 of about 186,361 (263)

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation. [PDF]

Aliment Pharmacol Ther
Niazi DMA, Charbel A, Pfeiffenberger J, Merle U, Seessle J, Wenz T, Flechtenmacher C, Michl P, Rauber C.   +8 more
europepmc   +1 more source

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

A Turning Point for Hepatitis C Care: Point-of-Care Hepatitis C Virus RNA Authorization as a Critical First Step Toward Integrated Test-and-Treat Models in the United States. [PDF]

Clin Infect Dis
Furukawa NW, Kamili S, Wester C.
europepmc   +1 more source

Prevalence of Hepatitis C Virus Antibody

Annals of Saudi Medicine, 2000
openaire   +2 more sources

Seroprevalence and Demographic Distribution of Blood-Borne Viral Infections among Hemodialysis Patients in Sudan: A Multicenter Study from Conflict-Affected Khartoum State. [PDF]

Virol J
Azhary A, Mohammed A, Almomen M, Hajhamed NM, Kabashi M, Mahgoub EAA, Muvunyi CM, Ahmed M, Alharbi BF, Siddig EE.   +9 more
europepmc   +1 more source

[Cryoglobulin and factors associated with it in patient with anti-hepatitis-C antibodies living in resource-limited countries]. [PDF]

Pan Afr Med J, 2019
Eloumou SAFB, Mefo'o JPN, Nga WTB, Kenfack GU, Yakana L, Malongue A, Okalla C, Kowo M, Andoulo FA, Tzeuton C, Bidja MSD, Namme HL, Adiogo D, Noah DN.   +13 more
europepmc   +1 more source

Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1. [PDF]

JCEM Case Rep
Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG.   +5 more
europepmc   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

A cross-border seroprevalence study on HBV, HCV, HDV and HIV in remote Amazonian communities on the border between French Guiana and Suriname. [PDF]

PLoS One
Schaub R, MacDonald-Ottevanger MS, Hoang S, Pisoni A, Bolloré K, Biche B, Neus A, Bisnajak R, Schinkel J, Blanc J, Grunberg A, Naldjinan R, Lucarelli A, Rousseau C, Michaud C, Gaillet M, Harkisoen S, Gordien E, Prins M, Tuaillon E, Nacher M, Vreden S.   +21 more
europepmc   +1 more source